|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Top Lists |
Insider Trading Graph View |
Insider Watch |
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise" - Peter Lynch ==>> What is insider trading>> |

| Transaction & Date | Reported Date |
Exercisable Expiration |
Company | Symbol | Insider Relationship | Shares Traded | Conversion Price |
Shares Ownership |
Filing |
| 2009-10-30 Purchase |
2009-11-03 7:28 pm | N/A N/A |
SUNESIS PHARMACEUTICALS INC | SNSS | Bay City Capital Management V LLC BAY CITY CAPITAL LLC Bay City Capital Fund V, L.P. Bay City Capital Fund V Co-Investment Fund LP (10% owner) | 326,936 | $0.22 | 980,809 (Direct) | View |
| 2009-10-30 Purchase |
2009-11-03 7:28 pm | N/A N/A | SUNESIS PHARMACEUTICALS INC | SNSS | Bay City Capital Management V LLC BAY CITY CAPITAL LLC Bay City Capital Fund V, L.P. Bay City Capital Fund V Co-Investment Fund LP (10% owner) | 6,230 | $0.22 | 18,690 (Direct) | View |
| 2009-10-30 Purchase |
2009-11-03 7:28 pm |
2009-10-30 2016-10-30 | SUNESIS PHARMACEUTICALS INC | SNSS | Bay City Capital Management V LLC BAY CITY CAPITAL LLC Bay City Capital Fund V, L.P. Bay City Capital Fund V Co-Investment Fund LP (10% owner) | 3,269,360 | $0.22 | 3,269,360 (Direct) |
View |
| 2009-10-30 Purchase | 2009-11-03 7:28 pm |
2009-10-30 2016-10-30 | SUNESIS PHARMACEUTICALS INC | SNSS | Bay City Capital Management V LLC BAY CITY CAPITAL LLC Bay City Capital Fund V, L.P. Bay City Capital Fund V Co-Investment Fund LP (10% owner) | 62,300 | $0.22 | 62,300 (Direct) | View |
|
© 2005-2009 SecForm4.Com All rights reserved. Archives: 2009 2008 2007 2006 2005 2004 ... Sun, 22 Nov 2009 04:36:14 -0600 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC. SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |